ReviewKidney international2012
Optimizing renal replacement therapy in older adults: a framework for making individualized decisions.
Review in Kidney international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Phosphate binders in chronic kidney disease: a systematic review of recent data.Journal of nephrology · 2016Pooled it
- Comparative outcomes of arteriovenous accesses with and without tunneled hemodialysis catheters: A retrospective cohort study.Medicine · 2026Article
- Decisional Conflict and Patient Experiences in Dialysis Treatment Decision-Making: A Mixed-Methods Study in a Portuguese Cohort.Healthcare (Basel, Switzerland) · 2026Article
- Screening for Geriatric Problems in Older Adults Receiving Hemodialysis Using a Self-Administered Battery.Clinical interventions in aging · 2026Article
- The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis.Kidney international reports · 2025Article
- Frailty in Kidney Disease: A Comprehensive Review to Advance Its Clinical and Research Applications.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Review
- The impact of quality of life on the survival of elderly patients with end-stage renal disease: a prospective multicenter cohort study in Korea.Clinical kidney journal · 2024Article
- The effect of dialysis modality on annual mortality: A prospective cohort study.Scientific reports · 2024Article
- A prospective, observational study of frailty, quality of life and dialysis in older people with advanced chronic kidney disease.BMC geriatrics · 2023Observational
- Association of Potentially Inappropriate Medication Classes with Mortality Risk Among Older Adults Initiating Hemodialysis.Drugs & aging · 2023Article
- Present and future of kidney replacement therapy in Italy: the perspective from Italian Dialysis and Transplantation Registry (IDTR).Journal of nephrology · 2020Review
- Vascular access placement and mortality in elderly incident hemodialysis patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Article
- Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population.Journal of the American Society of Nephrology : JASN · 2020Article
- Quality of life in older adults receiving hemodialysis: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- The Impact of Comorbidity Burden on The Association between Vascular Access Type and Clinical Outcomes among Elderly Patients Undergoing Hemodialysis.Scientific reports · 2019Article
- Effects of patient age on patency of chronic hemodialysis vascular access.BMC nephrology · 2019Observational
- Forearm loop arteriovenous grafts preserve and may create new upper arm access sites.The journal of vascular access · 2019Observational
- Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly.Drugs & aging · 2019Review
- Predicting long-term renal and patient survival by clinicopathological features in elderly patients undergoing a renal biopsy in a UK cohort.Clinical kidney journal · 2019Article
- Patency rates of arteriovenous fistulas created before versus after hemodialysis initiation.PloS one · 2019Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
It is often difficult to synthesize information about the risks and benefits of recommended management strategies in older patients with end-stage renal disease since they may have more comorbidity and lower life expectancy than patients described in clinical trials or practice guidelines. In this review, we outline a framework for individualizing end-stage renal disease management decisions in older patients. The framework considers three factors: life expectancy, the risks and benefits of competing treatment strategies, and patient preferences. We illustrate the use of this framework by applying it to three key end-stage renal disease decisions in older patients with varying life expectancy: choice of dialysis modality, choice of vascular access for hemodialysis, and referral for kidney transplantation. In several instances, this approach might provide support for treatment decisions that directly contradict available practice guidelines, illustrating circumstances when strict application of guidelines may be inappropriate for certain patients. By combining quantitative estimates of benefits and harms with qualitative assessments of patient preferences, clinicians may be better able to tailor treatment recommendations to individual older patients, thereby improving the overall quality of end-stage renal disease care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.